Explore Parabilis Medicines careers and hiring status. Find jobs at Parabilis Medicines and official application links when roles are open. Funding stage: IPO. Headcount: 51-200. Clinical-stage precision oncology company developing Helicon, a cell-penetrating peptide platform designed to target historically undruggable cancer targets such as beta-catenin. Its lead candidate, zolucatetide (FOG-001), is in clinical development across a range of solid tumors.
This page summarizes open roles, company profile signals, and official application paths so candidates can quickly evaluate fit before applying. Use the role list below to identify team focus, review location patterns, and jump to source listings. For broader comparison across the market, continue to the full company directory and jobs explorer.
Parabilis Medicines is a IPO stage AI startup, founded in 2015, with $1.45B in total disclosed funding. Its most recent round was a $745M IPO in Jun 2026. It has no open roles listed at the moment; new Parabilis Medicines openings are tracked daily. Source: Fast AI Jobs company dataset, updated Sep 2026.
Company profile last updated on Sep 11, 2026.
Parabilis Medicines careers and hiring status: no open roles are currently listed here, but you can review the company profile and check the official career page for the latest openings. Official careers page
Parabilis Medicines is an biotech company. Clinical-stage precision oncology company developing Helicon, a cell-penetrating peptide platform designed to target historically undruggable cancer targets such as beta-catenin. Its lead candidate, zolucatetide (FOG-001), is in clinical development across a range of solid tumors.
Open positions
Check the official career page, browse adjacent companies, or subscribe for new openings.
Candidate questions
Clinical-stage precision oncology company developing Helicon, a cell-penetrating peptide platform designed to target historically undruggable cancer targets such as beta-catenin. Its lead candidate, zolucatetide (FOG-001), is in clinical development across a range of solid tumors.
Parabilis Medicines does not have open roles listed on our platform right now. Visit the official company website or career page for the latest openings, or subscribe to get notified when new roles are posted.
Parabilis Medicines has raised $1.45B in total. The latest known stage is IPO.
Parabilis Medicines reports an employee count of 51-200.
Parabilis Medicines was founded in 2015.
Parabilis Medicines is associated with Biotech, Healthcare.
Company context
Parabilis Medicines is a IPO stage AI startup, founded in 2015, with $1.45B in total disclosed funding. Its most recent round was a $745M IPO in Jun 2026. It has no open roles listed at the moment; new Parabilis Medicines openings are tracked daily. Source: Fast AI Jobs company dataset, updated Sep 2026.